Validation of a Prognostic Multi-gene Signature in High-risk Neuroblastoma Using the High Throughput Digital NanoString NCounter™ System
Overview
Oncology
Authors
Affiliations
Microarray-based molecular signatures have not been widely integrated into neuroblastoma diagnostic classification systems due to the complexities of the assay and requirement for high-quality RNA. New digital technologies that accurately quantify gene expression using RNA isolated from formalin-fixed paraffin embedded (FFPE) tissues are now available. In this study, we describe the first use of a high-throughput digital system to assay the expression of genes in an "ultra-high risk" microarray classifier in FFPE high-risk neuroblastoma tumors. Customized probes corresponding to the 42 genes in a published multi-gene neuroblastoma signature were hybridized to RNA isolated from 107 FFPE high-risk neuroblastoma samples using the NanoString nCounter™ Analysis System. For classification of each patient, the Pearson's correlation coefficient was calculated between the standardized nCounter™ data and the molecular signature from the microarray data. We demonstrate that the nCounter™ 42-gene panel sub-stratified the high-risk cohort into two subsets with statistically significantly different overall survival (p = 0.0027) and event-free survival (p = 0.028). In contrast, none of the established prognostic risk markers (age, stage, tumor histology, MYCN status, and ploidy) were significantly associated with survival. We conclude that the nCounter™ System can reproducibly quantify expression levels of signature genes in FFPE tumor samples. Validation of this microarray signature in our high-risk patient cohort using a completely different technology emphasizes the prognostic relevance of this classifier. Prospective studies testing the prognostic value of molecular signatures in high-risk neuroblastoma patients using FFPE tumor samples and the nCounter™ System are warranted.
Implementation of a High-Accuracy Targeted Gene Expression Panel for Clinical Care.
Alontaga A, Cano P, Ozakinci H, Puskas J, Stewart P, Welsh E J Mol Diagn. 2024; 26(8):685-699.
PMID: 38777037 PMC: 11299514. DOI: 10.1016/j.jmoldx.2024.04.005.
Development and validation of a 21-gene prognostic signature in neuroblastoma.
Gupta M, Kannappan S, Jain M, Douglass D, Shah R, Bose P Sci Rep. 2023; 13(1):12526.
PMID: 37532697 PMC: 10397261. DOI: 10.1038/s41598-023-37714-9.
Melaiu O, Chierici M, Lucarini V, Jurman G, Conti L, De Vito R Nat Commun. 2020; 11(1):5992.
PMID: 33239635 PMC: 7689423. DOI: 10.1038/s41467-020-19781-y.
Yan W, Jamal M, Tan S, Song Y, Young D, Chen Y Oncotarget. 2019; 10(60):6466-6483.
PMID: 31741711 PMC: 6849651. DOI: 10.18632/oncotarget.27294.
McQuerry J, Jenkins D, Yost S, Zhang Y, Schmolze D, Johnson W BMC Cancer. 2019; 19(1):881.
PMID: 31488082 PMC: 6727561. DOI: 10.1186/s12885-019-6052-z.